Clinical Trial Detail

NCT ID NCT00411788
Title A Phase II Study of Rapamycin and Trastuzumab for Patients With HER-2 Receptor Positive Metastatic Breast Cancer
Recruitment Completed
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Yale University
Indications

Her2-receptor positive breast cancer

Therapies

Sirolimus + Trastuzumab

Age Groups: adult

Additional content available in CKB BOOST